Sanofi has presented promising late-stage data on U300, an improved version of its blockbuster insulin Lantus.
Results from two Phase III studies have been presented at the American Diabetes Association meeting in Chicago. The trials demonstrated that U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus (insulin glargine). Sanofi's head of diabetes, Pierre Chancel, said that “there remains a substantial unmet need in people with diabetes taking oral medication or insulin as many of them do not reach their glycaemic goals".
He added that U300, "we are striving to further enhance the clinical value of basal insulin, while building on the wealth of evidence of Lantus, the world’s most prescribed insulin". The latter is Sanofi's biggest-seller, and first-quarter sales reached 1.34 billion euros (+19.7%).
However, Lantus will be going off-patent in the next couple of years and Sanofi has high hopes it can be replaced by U300 as it has "even flatter and more prolonged profiles" than the blockbuster. The company also notes that this new formulation based on the glargine molecule "offers the benefit of a smaller volume of subcutaneous injection compared with Lantus".